WallStreetZenWallStreetZen

NASDAQ: ALLK
Allakos Inc Stock

$1.11+0.08 (+7.77%)
Updated Jun 21, 2024
ALLK Price
$1.11
Fair Value Price
$0.29
Market Cap
$98.28M
52 Week Low
$0.98
52 Week High
$5.64
P/E
-0.45x
P/B
0.95x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$214.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.71
Operating Cash Flow
-$119M
Beta
0.88
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALLK Overview

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALLK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALLK ($1.11) is overvalued by 285.77% relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALLK ($1.11) is not significantly undervalued (285.77%) relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALLK due diligence checks available for Premium users.

Be the first to know about important ALLK news, forecast changes, insider trades & much more!

ALLK News

Valuation

ALLK fair value

Fair Value of ALLK stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$0.29
Overvalued by
285.77%
ALLK ($1.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALLK ($1.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALLK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.45x
Industry
-5.75x
Market
30.75x

ALLK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.95x
Industry
6.2x
ALLK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALLK's financial health

Profit margin

Revenue
$0.0
Net Income
-$71.1M
Profit Margin
0%
ALLK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$177.3M
Liabilities
$73.3M
Debt to equity
0.71
ALLK's short-term assets ($147.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALLK's short-term assets ($147.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALLK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALLK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$32.5M
Investing
$9.0M
Financing
$132.0k
ALLK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALLK vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALLK$98.28M+7.77%-0.45x0.95x
BLUE$98.29M+5.27%-1.50x0.44x
BYSI$98.74M-2.32%-4.69x-3.68x
PDSB$96.83M+3.53%-1.93x2.60x
IMUX$99.99M0.00%-0.61x1.20x

Allakos Stock FAQ

What is Allakos's quote symbol?

(NASDAQ: ALLK) Allakos trades on the NASDAQ under the ticker symbol ALLK. Allakos stock quotes can also be displayed as NASDAQ: ALLK.

If you're new to stock investing, here's how to buy Allakos stock.

What is the 52 week high and low for Allakos (NASDAQ: ALLK)?

(NASDAQ: ALLK) Allakos's 52-week high was $5.64, and its 52-week low was $0.98. It is currently -80.32% from its 52-week high and 13.27% from its 52-week low.

How much is Allakos stock worth today?

(NASDAQ: ALLK) Allakos currently has 88,544,474 outstanding shares. With Allakos stock trading at $1.11 per share, the total value of Allakos stock (market capitalization) is $98.28M.

Allakos stock was originally listed at a price of $31.25 in Jul 19, 2018. If you had invested in Allakos stock at $31.25, your return over the last 5 years would have been -96.45%, for an annualized return of -48.7% (not including any dividends or dividend reinvestments).

How much is Allakos's stock price per share?

(NASDAQ: ALLK) Allakos stock price per share is $1.11 today (as of Jun 21, 2024).

What is Allakos's Market Cap?

(NASDAQ: ALLK) Allakos's market cap is $98.28M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Allakos's market cap is calculated by multiplying ALLK's current stock price of $1.11 by ALLK's total outstanding shares of 88,544,474.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.